1. Academic Validation
  2. Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration

Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration

  • Nat Commun. 2017 May 26;8:15584. doi: 10.1038/ncomms15584.
Hasini Jayatilaka 1 Pranay Tyle 1 Jonathan J Chen 2 Minsuk Kwak 2 Julia Ju 1 Hyun Ji Kim 1 Jerry S H Lee 1 3 Pei-Hsun Wu 1 4 Daniele M Gilkes 1 5 Rong Fan 2 Denis Wirtz 1 4 5
Affiliations

Affiliations

  • 1 Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA.
  • 2 Department of Biomedical Engineering, Yale University, New Haven, Connecticut 06520, USA.
  • 3 Center for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland 20850, USA.
  • 4 Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University, Baltimore, Maryland 21218, USA.
  • 5 Department of Oncology and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
Abstract

Following uncontrolled proliferation, a subset of primary tumour cells acquires additional traits/mutations to trigger phenotypic changes that enhance migration and are hypothesized to be the initiators of metastasis. This study reveals an adaptive mechanism that harnesses synergistic paracrine signalling via IL-6/8, which is amplified by cell proliferation and cell density, to directly promote cell migration. This effect occurs in metastatic human sarcoma and carcinoma cells- but not in normal or non-metastatic Cancer cells-, and likely involves the downstream signalling of WASF3 and Arp2/3. The transcriptional phenotype of high-density cells that emerges due to proliferation resembles that of low-density cells treated with a combination of IL-6/8. Simultaneous inhibition of IL-6/8 receptors decreases the expression of WASF3 and Arp2/3 in a mouse xenograft model and reduces metastasis. This study reveals a potential mechanism that promotes tumour cell migration and infers a strategy to decrease metastatic capacity of tumour cells.

Figures
Products